Influence of cancer-related inflammation on plasma disposition of osimertinib in patients with non-small cell lung cancer using the Glasgow prognostic score.

View at publisher Summarise with VIRAT
Authors: Tasuku Yokoyama, Natsu HAYASHI, Kazuhiro Asada, T Shirai, Tomonobu Uchino, Yasuharu Yazawa, Yoshiyuki Kagawa
Cited by: 0
References: 33

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Osimertinib, an EGFR tyrosine kinase inhibitor, is mainly metabolized by CYP3A. This study investigated genetic and non-genetic factors influencing plasma osimertinib concentrations in 36 patients with non-small cell lung cancer. Changes in CYP3A activity were evaluated using its endogenous marker, 4β-hydroxycholesterol (4β-OHC).

Fields of Study & Subjects

Pharmacogenetics and Drug Metabolism Lung Cancer Treatments and Mutations Drug Transport and Resistance Mechanisms

Publication details

Journal / source
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
Volume
57
Issue
2
Pages
6–14
Publication date
1 January 2026
Language
EN